A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Known, active, or uncontrolled central nervous system (CNS) metastasis or carcinomatous meningitis.
• •Has AEs due to previous anti-tumor treatments not recovered to ≤Grade 1 (except for alopecia; some tolerable chronic toxicities of Grade 2 may be excluded after consultation with the sponsor, as judged by the investigator) according to NCI-CTCAE v5.0.
• •Any serious and/or uncontrolled concurrent illness that may interfere with study participation
• •Prior therapy
• •Received other investigational drugs or treatments within 4 weeks before the first dose of the investigational drug in the study
• •The time interval between the latest anti-tumor treatment and the first dose of the investigational drug meets the following requirements: Have received anti-tumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy and other clinical investigational drugs within 4 weeks before the first dose of the investigational drug; have received oral fluoropyrimidines, small molecule targeted drugs within 2 weeks before the first dose of the investigational drug; have received palliative radiotherapy or local therapy within 2 weeks before the first dose of investigational drug.
• •Had major surgery within 4 weeks before the first dose of the investigational drug in the study.